| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Evidence of emerging resistance to chloroquine by Plasmodium vivax is described from Irian Jaya (Indonesian New Guinea). Sixteen of 24 residents in the village of Arso PIR II taking supervised weekly chloroquine prophylaxis (5 mg base/kg) had asexual parasitemia with P. vivax at least once during eight weeks of surveillance. An American working in the same village developed symptomatic P. vivax parasitemia despite chloroquine prophylaxis. Five days after therapy with 600 mg chloroquine base, the asexual parasitemia in the American increased 40-fold, but cleared after treatment with 1, 500 mg chloroquine base. Serum samples were not available from many of the cases, but six local residents and the American had serum levels of chloroquine in excess of the ordinarily suppressive 15 ng/ml at the time of their asexual parasitemias (16–70 ng/ml). The weekly 300 mg base tablet of chloroquine, which has been the standard for prophylaxis against malaria for more than 40 years, was not effective against P. vivax in Arso PIR, Irian Jaya.
This article has been cited by other articles:
|
|
 |
|
  C. Barnadas, A. Ratsimbasoa, M. Tichit, C. Bouchier, M. Jahevitra, S. Picot, and D. Menard Plasmodium vivax Resistance to Chloroquine in Madagascar: Clinical Efficacy and Polymorphisms in pvmdr1 and pvcrt-o Genes Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4233 - 4240. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Schlagenhauf and E. Petersen Malaria Chemoprophylaxis: Strategies for Risk Groups Clin. Microbiol. Rev., July 1, 2008; 21(3): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Russell, F. Chalfein, B. Prasetyorini, E. Kenangalem, K. Piera, R. Suwanarusk, A. Brockman, P. Prayoga, P. Sugiarto, Q. Cheng, et al. Determinants of In Vitro Drug Susceptibility Testing of Plasmodium vivax Antimicrob. Agents Chemother., March 1, 2008; 52(3): 1040 - 1045. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. N. Price, E. Tjitra, C. A. Guerra, S. Yeung, N. J. White, and N. M. Anstey Vivax Malaria: Neglected and Not Benign Am J Trop Med Hyg, December 1, 2007; 77(6_Suppl): 79 - 87. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Druilhe, P. Brasseur, C. Blanc, and M. Makler Improved Assessment of Plasmodium vivax Response to Antimalarial Drugs by a Colorimetric Double-Site Plasmodium Lactate Dehydrogenase Antigen Capture Enzyme-Linked Immunosorbent Assay Antimicrob. Agents Chemother., June 1, 2007; 51(6): 2112 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H. Chen, M. E. Wilson, and P. Schlagenhauf Controversies and Misconceptions in Malaria Chemoprophylaxis for Travelers JAMA, May 23, 2007; 297(20): 2251 - 2263. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. AULIFF, D. W. WILSON, B. RUSSELL, Q. GAO, N. CHEN, L. N. ANH, J. MAGUIRE, D. BELL, M. T. O'NEIL, and Q. CHENG AMINO ACID MUTATIONS IN PLASMODIUM VIVAX DHFR AND DHPS FROM SEVERAL GEOGRAPHICAL REGIONS AND SUSCEPTIBILITY TO ANTIFOLATE DRUGS. Am J Trop Med Hyg, October 1, 2006; 75(4): 617 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Hastings and C. H. Sibley Pyrimethamine and WR99210 exert opposing selection on dihydrofolate reductase from Plasmodium vivax PNAS, October 1, 2002; 99(20): 13137 - 13141. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Viani and K. Bromberg Pediatric Imported Malaria in New York: Delayed Diagnosis Clinical Pediatrics, July 1, 1999; 38(6): 333 - 337. [Abstract] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
